| P50 | author | William Hope | Q37370273 |
| P2093 | author name string | Peter A Warn | |
| | Joanne Goodwin | |
| | Lea Gregson | |
| | Susan J Howard | |
| | Zaid Al-Nakeeb | |
| | Adam R Jeans | |
| P2860 | cites work | Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure | Q42555868 |
| | In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. | Q42949201 |
| | Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions | Q43183398 |
| | Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study | Q43198289 |
| | An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients | Q43258660 |
| | Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus | Q44418762 |
| | Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin | Q44469440 |
| | Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis | Q45063490 |
| | Combination antifungal therapy for invasive aspergillosis | Q45096994 |
| | Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications | Q45242201 |
| | Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis | Q46607530 |
| | Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study | Q46943408 |
| | Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints. | Q47568169 |
| | Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. | Q51186517 |
| | EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia–forming moulds | Q56837279 |
| | Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis | Q61758327 |
| | Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease | Q77734361 |
| | When a paradoxical increase in serum galactomannan antigen during caspofungin therapy is not paradoxical after all | Q79719627 |
| | Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis | Q79804764 |
| | Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients | Q83131195 |
| | Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 |
| | Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America | Q28263689 |
| | In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates | Q28345261 |
| | Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism | Q30853962 |
| | Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase | Q33754208 |
| | Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis | Q33769712 |
| | Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus | Q33857685 |
| | Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis | Q34045435 |
| | Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia | Q34104748 |
| | Uptake of Aspergillus fumigatus Conidia by phagocytic and nonphagocytic cells in vitro: quantitation using strains expressing green fluorescent protein | Q34122696 |
| | Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy | Q34754956 |
| | Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition | Q35194409 |
| | Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients | Q35270270 |
| | Population pharmacokinetics of voriconazole in adults | Q35666490 |
| | In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus | Q36492208 |
| | The pharmacology and clinical use of caspofungin | Q36788428 |
| | Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin | Q37190801 |
| | Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis | Q37204192 |
| | Therapy for fungal diseases: opportunities and priorities | Q37703949 |
| | Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis | Q39652561 |
| | The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro | Q39652699 |
| | In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. | Q39652771 |
| | Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy | Q40186278 |
| | The search for synergy: a critical review from a response surface perspective. | Q40417895 |
| | Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. | Q42286250 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Aspergillus fumigatus | Q134359 |
| | aspergillosis | Q259626 |
| | voriconazole | Q412236 |
| | infectious disease | Q18123741 |
| | invasive pulmonary aspergillosis | Q54946623 |
| P304 | page(s) | 5180-5 | |
| P577 | publication date | 2012-10-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis | |
| P478 | volume | 56 | |